Topical 5-fluorouracil with photodynamic therapy as good as excision in Bowen's disease
Topical 5% 5-fluorouracil with photodynamic therapy as good as excision in Bowen's disease suggests a new study published in the Journal of the American Academy of Dermatology.
Randomized controlled trials comparing the effectiveness of 5-fluorouracil cream, methylaminolevulinate photodynamic therapy (MAL-PDT) and surgical excision in patients with Bowen's disease are lacking. background METHODS: In this multicenter non-inferiority trial, patients with a histologically proven Bowen's disease of 4-40mm were randomly assigned to excision with 5mm margin, 5% 5-fluorouracil cream twice daily for four weeks, or two sessions of MAL-PDT with one week interval. The primary outcome was the proportion of patients with sustained clearance at 12 months after treatment. A non-inferiority margin of 22% was used.
Results:
Between May 2019 and January 2021, 250 patients were randomized. The proportion of patients with sustained clearance was 97.4% (75/77) after excision, 85.7% (66/77) after 5-fluorouracil and 82.1% (64/78) after MAL-PDT. Absolute differences were -11.7% (95% CI -18.9 to -4.5; P=0.0049) for 5-fluorouracil versus excision and -15.4% (95% CI -23.1 to -7.6; P=0.00078) for MAL-PDT versus excision. Both non-invasive treatments significantly more often led to good or excellent cosmetic outcome.
Based on our predefined non-inferiority margin of 22%, 5-fluorourcail is non-inferior to excision and associated with better cosmetic outcome. For MAL-PDT non-inferiority to excision cannot be concluded. Therefore, 5-fluorouracil should be preferred over excision and MAL-PDT in treatment of Bowen's disease.
Reference:
Ahmady S, Nelemans PJ, Kelleners-Smeets NWJ, Arits AHMM, de Rooij MJM, Kessels JPHM, Essers BAB, Mosterd K. Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in treatment of Bowen's disease: a multicenter randomized controlled trial. J Am Acad Dermatol. 2023 Sep 2:S0190-9622(23)02662-2. doi: 10.1016/j.jaad.2023.08.076. Epub ahead of print. PMID: 37666424.
Keywords:
Topical, 5% 5-fluorouracil, photodynamic, therapy, as, good, excision, Bowen's disease, Ahmady S, Nelemans PJ, Kelleners-Smeets NWJ, Arits AHMM, de Rooij MJM, Kessels JPHM, Essers BAB, Mosterd K, Bowen’s disease; Squamous cell carcinoma; clinical research; drug response; fluorouracil; general dermatology; medical dermatology; oncology; photodynamic Therapy; skin cancer; surgery; therapy.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.